Log in

NASDAQ:AKROAkero Therapeutics Stock Price, Forecast & News

-2.25 (-5.64 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $37.67
50-Day Range
MA: $26.71
52-Week Range
Now: $37.67
Volume598,200 shs
Average Volume616,629 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKRO



Sales & Book Value

Annual SalesN/A
Book Value$4.51 per share


Net Income$-43,760,000.00


Market Cap$1.08 billion
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive AKRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.

Akero Therapeutics (NASDAQ:AKRO) Frequently Asked Questions

How has Akero Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akero Therapeutics' stock was trading at $21.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AKRO stock has increased by 79.3% and is now trading at $37.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akero Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akero Therapeutics.

When is Akero Therapeutics' next earnings date?

Akero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Akero Therapeutics.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics (NASDAQ:AKRO) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.61) by $0.19. View Akero Therapeutics' earnings history.

What price target have analysts set for AKRO?

7 brokers have issued 1-year price targets for Akero Therapeutics' shares. Their forecasts range from $34.00 to $79.00. On average, they expect Akero Therapeutics' stock price to reach $47.57 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts' price targets for Akero Therapeutics.

Has Akero Therapeutics been receiving favorable news coverage?

Media coverage about AKRO stock has been trending negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akero Therapeutics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Akero Therapeutics.

Are investors shorting Akero Therapeutics?

Akero Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 515,700 shares, a decrease of 9.4% from the June 15th total of 569,300 shares. Based on an average daily volume of 203,600 shares, the days-to-cover ratio is presently 2.5 days. Approximately 5.0% of the shares of the company are sold short. View Akero Therapeutics' Current Options Chain.

Who are some of Akero Therapeutics' key competitors?

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Stoke Therapeutics (STOK), Gilead Sciences (GILD), LogicBio Therapeutics (LOGC), Pfizer (PFE), Precision BioSciences (DTIL), II-VI (IIVI) and Kaleido Biosciences (KLDO).

Who are Akero Therapeutics' key executives?

Akero Therapeutics' management team includes the following people:
  • Dr. Andrew Cheng, Pres, Chief Exec. Officer & Director (Age 52)
  • Dr. Jonathan M. Young, Co-Founder, EVP & COO (Age 49)
  • Mr. Timothy Rolph, Co-Founder & Chief Scientific Officer (Age 65)
  • Mr. William R. White, EVP, CFO & Head of Corp. Devel. (Age 46)
  • Ms. Kitty Yale, Chief Devel. Officer (Age 47)

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

How do I buy shares of Akero Therapeutics?

Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $37.67.

How big of a company is Akero Therapeutics?

Akero Therapeutics has a market capitalization of $1.08 billion. The company earns $-43,760,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Akero Therapeutics employs 8 workers across the globe.

What is Akero Therapeutics' official website?

The official website for Akero Therapeutics is www.akerotx.com.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-487-6488 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.